GSK - VBI Vaccines updated phase 2 glioblastoma data shows continued overall survival benefit

Updated phase 2 data from VBI Vaccines' (NASDAQ:VBIV) cancer vaccine candidate VBI-1901 found 18-month overall survival of 25% in one arm and 40% in another in recurrent glioblastoma (GBM). In the first arm, VBI-1901 was adjuvanted with granulocyte macrophage colony-stimulating factor (GM-CSF). In the second, the vaccine was given with GlaxoSmithKline's (GSK) AS01B Adjuvant System2 VBI Vaccines (VBIV) said it will add patients in the current trial and add a control arm in Q3. The company added it plans to initiate a phase 2 trial of VBI-1901 in primary GBM in Q4. VBI Vaccines' (VBIV) hepatitis b vaccine PreHevbri recently won approval in the U.K.

For further details see:

VBI Vaccines updated phase 2 glioblastoma data shows continued overall survival benefit